Browsing Tag
IDEAYA Biosciences
3 posts
IDEAYA Biosciences (IDYA) stock in focus as ASCO 2026 late-breaker sets up fuller OptimUM-02 readout
IDEAYA Biosciences heads to ASCO 2026 with full OptimUM-02 data. Read why the late-breaking slot could matter for IDYA stock and melanoma strategy.
How the OptimUM-02 trial timeline may influence investor and clinical sentiment in ocular oncology
IDEAYA Biosciences nears darovasertib data. Find out how this Phase 3 readout could reshape metastatic uveal melanoma treatment today.
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.